Global and United States Antitumor Drugs of Hormone Class In-Depth Research Report 2017-2022

August 2017 | 117 pages | ID: GE1965FBA04EN
US Market Insights (UMI)

Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Antitumor Drugs of Hormone Class industry.

Major Companies

• PHARMACIA AND UPJOHN
• LILLY
• TEVA PHARMS USA
• WEST-WARD PHARMS INT
• NOVARTIS PHARMS
• MYLAN
• ASTRAZENECA
• SCHERING
• PAR PHARM
• CONCORDIA PHARMS INC
• ANI PHARMS INC
• KYOWA KIRIN

Key Regions

• North America
• United States
• California
• Texas
• New York
• Others
• Canada
• Latin America
• Mexico
• Brazil
• Argentina
• Others
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Netherland
• Others
• Asia & Pacific
• China
• Japan
• India
• Korea
• Australia
• Southeast Asia
• Indonesia
• Thailand
• Philippines
• Vietnam
• Singapore
• Malaysia
• Others
• Africa & Middle East
• South Africa
• Egypt
• Turkey
• Saudi Arabia
• Iran
• Others

Main types of products

Antitumor Drugs of Hormone Class Market, by Hormone Class

• Exemestane
• Raloxifene
• Letrozole
• Fulvestrant
• Anastrozole
• Flutamide
• Droloxifene
• Idoxifene
• Formestane
• Aminoglutethimide
• Nilutamide
• Tamoxifen
• Toremifene
• Aminoglutethimide

Antitumor Drugs of Hormone Class Market, by Key Consumers

• Oncology Department
• Hospital
• Department of Chemotherapy
• Pharmacology

Contents

CHAPTER ONE GLOBAL ANTITUMOR DRUGS OF HORMONE CLASS MARKET OVERVIEW

1.1 Global Antitumor Drugs of Hormone Class Market Sales Volume Revenue and Price 2012-2017
1.2 Antitumor Drugs of Hormone Class, by Hormone Class 2012-2017
  1.2.1 Global Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class 2012-2017
  1.2.2 Global Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class 2012-2017
  1.2.3 Global Antitumor Drugs of Hormone Class Price by Hormone Class 2012-2017
  1.2.4 Exemestane
  1.2.5 Raloxifene
  1.2.6 Letrozole
  1.2.7 Fulvestrant
  1.2.8 Anastrozole
Flutamide
Droloxifene
Idoxifene
Formestane
Aminoglutethimide
Nilutamide
Tamoxifen
Toremifene
Aminoglutethimide

CHAPTER TWO UNITED STATES ANTITUMOR DRUGS OF HORMONE CLASS MARKET OVERVIEW

2.1 United States Antitumor Drugs of Hormone Class Market Sales Volume Revenue and Price 2012-2017
2.2 Antitumor Drugs of Hormone Class, by Hormone Class 2012-2017
  2.2.1 United States Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class 2012-2017
  2.2.2 United States Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class 2012-2017
  2.2.3 United States Antitumor Drugs of Hormone Class Price by Hormone Class 2012-2017
  2.2.4 Exemestane
  2.2.5 Raloxifene
  2.2.6 Letrozole
  2.2.7 Fulvestrant
  2.2.8 Anastrozole
Flutamide
Droloxifene
Idoxifene
Formestane
Aminoglutethimide
Nilutamide
Tamoxifen
Toremifene
Aminoglutethimide

CHAPTER THREE ANTITUMOR DRUGS OF HORMONE CLASS BY REGIONS 2012-2017

3.1 Global Antitumor Drugs of Hormone Class Sales Market Share by Regions 2012-2017
3.2 Global Antitumor Drugs of Hormone Class Revenue Market Share by Regions 2012-2017
3.3 Global Antitumor Drugs of Hormone Class Price by Regions 2012-2017
3.4 North America
  3.4.1 United States
    3.4.1.1 California
    3.4.1.2 Texas
    3.4.1.3 New York
    3.4.1.4 Others in United States
  3.4.2 Canada
3.5 Latin America
  3.5.1 Mexico
  3.5.2 Brazil
  3.5.3 Argentina
  3.5.4 Others in Latin America
3.6 Europe
  3.6.1 Germany
  3.6.2 United Kingdom
  3.6.3 France
  3.6.4 Italy
  3.6.5 Spain
  3.6.6 Russia
  3.6.7 Netherland
  3.6.8 Others in Europe
3.7 Asia & Pacific
  3.7.1 China
  3.7.2 Japan
  3.7.3 India
  3.7.4 Korea
  3.7.5 Australia
  3.7.6 Southeast Asia
    3.7.6.1 Indonesia
    3.7.6.2 Thailand
    3.7.6.3 Philippines
    3.7.6.4 Vietnam
    3.7.6.5 Singapore
    3.7.6.6 Malaysia
    3.7.6.7 Others in Southeast Asia
3.8 Africa & Middle East
  3.8.1 South Africa
  3.8.2 Egypt
  3.8.3 Turkey
  3.8.4 Saudi Arabia
  3.8.5 Iran
  3.8.6 Others in Africa & Middle East

CHAPTER FOUR GLOBAL ANTITUMOR DRUGS OF HORMONE CLASS BY COMPANIES 2012-2017

4.1 Global Antitumor Drugs of Hormone Class Sales Volume Market Share by Companies 2012-2017
4.2 Global Antitumor Drugs of Hormone Class Revenue Share by Companies 2012-2017
4.3 Global Top Companies Antitumor Drugs of Hormone Class Key Product Model and Market Performance
4.4 Global Top Companies Antitumor Drugs of Hormone Class Key Target Consumers and Market Performance

CHAPTER FIVE UNITED STATES ANTITUMOR DRUGS OF HORMONE CLASS BY COMPANIES 2012-2017

5.1 United States Antitumor Drugs of Hormone Class Sales Volume Market Share by Companies 2012-2017
5.2 United States Antitumor Drugs of Hormone Class Revenue Share by Companies 2012-2017
5.3 United States Top Companies Antitumor Drugs of Hormone Class Key Product Model and Market Performance
5.4 United States Top Companies Antitumor Drugs of Hormone Class Key Target Consumers and Market Performance

CHAPTER SIX GLOBAL ANTITUMOR DRUGS OF HORMONE CLASS BY CONSUMER 2012-2017

6.1 Global Antitumor Drugs of Hormone Class Sales Market Share by Consumer 2012-2017
6.2 Oncology Department
6.3 Hospital
6.4 Department of Chemotherapy
6.5 Pharmacology
6.6 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL ANTITUMOR DRUGS OF HORMONE CLASS BY CONSUMER 2012-2017

7.1 Global Antitumor Drugs of Hormone Class Sales Market Share by Consumer 2012-2017
7.2 Oncology Department
7.3 Hospital
7.4 Department of Chemotherapy
7.5 Pharmacology
7.6 Consuming Habit and Preference

CHAPTER EIGHT TOP COMPANIES PROFILE

8.1 PHARMACIA AND UPJOHN
  8.1.1 PHARMACIA AND UPJOHN Company Details and Competitors
  8.1.2 PHARMACIA AND UPJOHN Key Antitumor Drugs of Hormone Class Models and Performance
  8.1.3 PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.1.4 PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.2 LILLY
  8.2.1 LILLY Company Details and Competitors
  8.2.2 LILLY Key Antitumor Drugs of Hormone Class Models and Performance
  8.2.3 LILLY Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.2.4 LILLY Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.3 TEVA PHARMS USA
  8.3.1 TEVA PHARMS USA Company Details and Competitors
  8.3.2 TEVA PHARMS USA Key Antitumor Drugs of Hormone Class Models and Performance
  8.3.3 TEVA PHARMS USA Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.3.4 TEVA PHARMS USA Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.4 WEST-WARD PHARMS INT
  8.4.1 WEST-WARD PHARMS INT Company Details and Competitors
  8.4.2 WEST-WARD PHARMS INT Key Antitumor Drugs of Hormone Class Models and Performance
  8.4.3 WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.4.4 WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.5 NOVARTIS PHARMS
  8.5.1 NOVARTIS PHARMS Company Details and Competitors
  8.5.2 NOVARTIS PHARMS Key Antitumor Drugs of Hormone Class Models and Performance
  8.5.3 NOVARTIS PHARMS Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.5.4 NOVARTIS PHARMS Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.6 MYLAN
  8.6.1 MYLAN Company Details and Competitors
  8.6.2 MYLAN Key Antitumor Drugs of Hormone Class Models and Performance
  8.6.3 MYLAN Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.6.4 MYLAN Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.7 ASTRAZENECA
  8.7.1 ASTRAZENECA Company Details and Competitors
  8.7.2 ASTRAZENECA Key Antitumor Drugs of Hormone Class Models and Performance
  8.7.3 ASTRAZENECA Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.7.4 ASTRAZENECA Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.8 SCHERING
  8.8.1 SCHERING Company Details and Competitors
  8.8.2 SCHERING Key Antitumor Drugs of Hormone Class Models and Performance
  8.8.3 SCHERING Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.8.4 SCHERING Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.9 PAR PHARM
  8.9.1 PAR PHARM Company Details and Competitors
  8.9.2 PAR PHARM Key Antitumor Drugs of Hormone Class Models and Performance
  8.9.3 PAR PHARM Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.9.4 PAR PHARM Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.10 CONCORDIA PHARMS INC
  8.10.1 CONCORDIA PHARMS INC Company Details and Competitors
  8.10.2 CONCORDIA PHARMS INC Key Antitumor Drugs of Hormone Class Models and Performance
  8.10.3 CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
  8.10.4 CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Sales Volume Revenue Price Cost and Gross Margin
8.11 ANI PHARMS INC
8.12 KYOWA KIRIN

CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN

9.1 Antitumor Drugs of Hormone Class Industry Chain Structure
  9.1.1 R&D
  9.1.2 Raw Materials (Components)
  9.1.3 Manufacturing Plants
  9.1.4 Regional Trading (Import Export and Local Sales)
  9.1.5 Online Sales Channel
  9.1.6 Offline Channel
  9.1.7 End Users
9.2 Antitumor Drugs of Hormone Class Manufacturing
  9.2.1 Key Components
  9.2.2 Assembly Manufacturing
9.3 Consumer Preference
9.4 Behavioral Habits
9.5 Marketing Environment

CHAPTER TEN GLOBAL ANTITUMOR DRUGS OF HORMONE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

10.1 Global Antitumor Drugs of Hormone Class Sales (), Revenue (Million USD) Forecast (2017-2022)
10.2 Global Antitumor Drugs of Hormone Class Sales () Forecast by Regions (2017-2022)
10.3 Global Antitumor Drugs of Hormone Class Sales () Forecast by Application (2017-2022)
10.4 Global Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
10.5 Global Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)

CHAPTER ELEVEN UNITED STATES ANTITUMOR DRUGS OF HORMONE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 United States Antitumor Drugs of Hormone Class Sales (), Revenue (Million USD) Forecast (2017-2022)
11.2 United States Antitumor Drugs of Hormone Class Sales () Forecast by Regions (2017-2022)
11.3 United States Antitumor Drugs of Hormone Class Sales () Forecast by Application (2017-2022)
11.4 United States Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
11.5 United States Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)

CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION

12.1 Development Trend
12.2 Research Conclusion

CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Antitumor Drugs of Hormone Class Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure Global Antitumor Drugs of Hormone Class Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Volume () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales () by Hormone Class (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class in 2016
Table Global Antitumor Drugs of Hormone Class Revenue (Million USD) by Hormone Class (2012-2017)
Table Global Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class in 2016
Table Global Antitumor Drugs of Hormone Class Price () by Hormone Class (2012-2017)
Table Top Companies of Exemestane Antitumor Drugs of Hormone Class Products List
Figure Global Exemestane Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Raloxifene Antitumor Drugs of Hormone Class Products List
Figure Global Raloxifene Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Letrozole Antitumor Drugs of Hormone Class Products List
Figure Global Letrozole Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Fulvestrant Antitumor Drugs of Hormone Class Products List
Figure Global Fulvestrant Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Anastrozole Antitumor Drugs of Hormone Class Products List
Figure Global Anastrozole Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales () by (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales Market Share by (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by in 2016
Table Global Antitumor Drugs of Hormone Class Revenue (Million USD) by (2012-2017)
Table Global Antitumor Drugs of Hormone Class Revenue Market Share by (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by in 2016
Table Global Antitumor Drugs of Hormone Class Price () by (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Revenue (Million USD) and Growth Rate (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Volume () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales () by Hormone Class (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Market Share by Hormone Class in 2016
Table United States Antitumor Drugs of Hormone Class Revenue (Million USD) by Hormone Class (2012-2017)
Table United States Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Revenue Market Share by Hormone Class in 2016
Table United States Antitumor Drugs of Hormone Class Price () by Hormone Class (2012-2017)
Table Top Companies of Exemestane Antitumor Drugs of Hormone Class Products List
Figure United States Exemestane Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Raloxifene Antitumor Drugs of Hormone Class Products List
Figure United States Raloxifene Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Letrozole Antitumor Drugs of Hormone Class Products List
Figure United States Letrozole Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Fulvestrant Antitumor Drugs of Hormone Class Products List
Figure United States Fulvestrant Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Anastrozole Antitumor Drugs of Hormone Class Products List
Figure United States Anastrozole Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales () by (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales Market Share by (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Market Share by in 2016
Table United States Antitumor Drugs of Hormone Class Revenue (Million USD) by (2012-2017)
Table United States Antitumor Drugs of Hormone Class Revenue Market Share by (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Revenue Market Share by in 2016
Table United States Antitumor Drugs of Hormone Class Price () by (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales Share by Regions (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by Regions in 2016
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by Regions in 2017
Table Global Antitumor Drugs of Hormone Class Revenue (Million USD) and Market Share by Regions (2012-2017)
Table Global Antitumor Drugs of Hormone Class Revenue Market Share by Regions (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by Regions in 2016
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by Regions in 2017
Table Global Antitumor Drugs of Hormone Class Price () by Regions (2012-2017)
Table North America Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table North America Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure North America Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table United States Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Latin America Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table Latin America Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure Latin America Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Europe Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table Europe Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure Europe Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Asia & Pacific Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table Asia & Pacific Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure Asia & Pacific Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Africa & Middle East Antitumor Drugs of Hormone Class Sales () by Regions (2012-2017)
Table Africa & Middle East Antitumor Drugs of Hormone Class Revenue (Million USD) by Regions (2012-2017)
Figure Africa & Middle East Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales Volume () by Major Companies (2012-2017)
Table Global Antitumor Drugs of Hormone Class Sales Volume Market Share by Major Companies (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share by Major Companies 2016
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share by Major Companies 2017
Table Global Antitumor Drugs of Hormone Class Revenue (Million USD) by Major Companies (2012-2017)
Table Global Antitumor Drugs of Hormone Class Revenue Market Share by Major Companies (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by Major Companies 2016
Figure Global Antitumor Drugs of Hormone Class Revenue Market Share by Major Companies 2017
Table Global Top Companies Key Product Model and Market Performance
Table Global Top Companies Key Target Consumers and Market Performance
Table United States Antitumor Drugs of Hormone Class Sales Volume () by Top Companies (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales Volume Market Share by Top Companies (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share by Top Companies 2016
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share by Top Companies 2017
Table United States Antitumor Drugs of Hormone Class Revenue (Million USD) by Top Companies (2012-2017)
Table United States Antitumor Drugs of Hormone Class Revenue Market Share by Top Companies (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Revenue Market Share by Top Companies 2016
Figure United States Antitumor Drugs of Hormone Class Revenue Market Share by Top Companies 2017
Table United States Top Companies Key Product Model and Market Performance
Table United States Top Companies Key Target Consumers and Market Performance
Table Global Antitumor Drugs of Hormone Class Sales () by Consumer (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by Consumer (2012-2017)
Figure Global Antitumor Drugs of Hormone Class Sales Market Share by Consumer in 2016
Figure Global Oncology Department Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure Global Hospital Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure Global Department of Chemotherapy Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure Global Pharmacology Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Hormone Class Sales () by Consumer (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Market Share by Consumer (2012-2017)
Figure United States Antitumor Drugs of Hormone Class Sales Market Share by Consumer in 2016
Figure United States Oncology Department Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure United States Hospital Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure United States Department of Chemotherapy Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Figure United States Pharmacology Antitumor Drugs of Hormone Class Sales () and Growth Rate (2012-2017)
Table PHARMACIA AND UPJOHN Company Details and Competitors
Table PHARMACIA AND UPJOHN Key Antitumor Drugs of Hormone Class Models and Performance
Table PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure PHARMACIA AND UPJOHN Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table LILLY Company Details and Competitors
Table LILLY Key Antitumor Drugs of Hormone Class Models and Performance
Table LILLY Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table LILLY Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure LILLY Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure LILLY Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure LILLY Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure LILLY Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table TEVA PHARMS USA Company Details and Competitors
Table TEVA PHARMS USA Key Antitumor Drugs of Hormone Class Models and Performance
Table TEVA PHARMS USA Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table TEVA PHARMS USA Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure TEVA PHARMS USA Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure TEVA PHARMS USA Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure TEVA PHARMS USA Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure TEVA PHARMS USA Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table WEST-WARD PHARMS INT Company Details and Competitors
Table WEST-WARD PHARMS INT Key Antitumor Drugs of Hormone Class Models and Performance
Table WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure WEST-WARD PHARMS INT Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table NOVARTIS PHARMS Company Details and Competitors
Table NOVARTIS PHARMS Key Antitumor Drugs of Hormone Class Models and Performance
Table NOVARTIS PHARMS Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table NOVARTIS PHARMS Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure NOVARTIS PHARMS Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure NOVARTIS PHARMS Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure NOVARTIS PHARMS Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure NOVARTIS PHARMS Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table MYLAN Company Details and Competitors
Table MYLAN Key Antitumor Drugs of Hormone Class Models and Performance
Table MYLAN Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table MYLAN Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure MYLAN Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure MYLAN Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure MYLAN Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure MYLAN Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table ASTRAZENECA Company Details and Competitors
Table ASTRAZENECA Key Antitumor Drugs of Hormone Class Models and Performance
Table ASTRAZENECA Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table ASTRAZENECA Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure ASTRAZENECA Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure ASTRAZENECA Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure ASTRAZENECA Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure ASTRAZENECA Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table SCHERING Company Details and Competitors
Table SCHERING Key Antitumor Drugs of Hormone Class Models and Performance
Table SCHERING Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table SCHERING Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure SCHERING Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure SCHERING Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure SCHERING Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure SCHERING Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table PAR PHARM Company Details and Competitors
Table PAR PHARM Key Antitumor Drugs of Hormone Class Models and Performance
Table PAR PHARM Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table PAR PHARM Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure PAR PHARM Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure PAR PHARM Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure PAR PHARM Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure PAR PHARM Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table CONCORDIA PHARMS INC Company Details and Competitors
Table CONCORDIA PHARMS INC Key Antitumor Drugs of Hormone Class Models and Performance
Table CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Business SWOT Analysis and Forecast
Table CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Sales Market Share (%) in Global (2012-2017)
Figure CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure CONCORDIA PHARMS INC Antitumor Drugs of Hormone Class Revenue Market Share (%) in Global (2012-2017)
Table ANI PHARMS INC Company Details and Competitors
Table KYOWA KIRIN Company Details and Competitors
Figure Global Antitumor Drugs of Hormone Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Price () Trend Forecast (2017-2022)
Table Global Antitumor Drugs of Hormone Class Sales () Forecast by Regions (2017-2022)
Table Global Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions in 2022
Table Global Antitumor Drugs of Hormone Class Sales () Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Application in 2022
Table Global Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Hormone Class in 2022
Table Global Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)
Figure Global Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by in 2022
Figure United States Antitumor Drugs of Hormone Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Price () Trend Forecast (2017-2022)
Table United States Antitumor Drugs of Hormone Class Sales () Forecast by Regions (2017-2022)
Table United States Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Share Forecast by Regions in 2022
Table United States Antitumor Drugs of Hormone Class Sales () Forecast by Application (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Application in 2022
Table United States Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales () Forecast by Hormone Class (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by Hormone Class in 2022
Table United States Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales () Forecast by (2017-2022)
Figure United States Antitumor Drugs of Hormone Class Sales Volume Market Share Forecast by in 2022